Inspire Medical Systems develops Inspire Upper Airway Stimulation, an FDA-approved implantable neurostimulation system for some people with moderate to severe obstructive sleep apnea who are unable to use or get consistent benefit from CPAP. The system is implanted and controlled by a small handheld sleep remote and includes a breathing sensor and a stimulation lead that delivers mild stimulation to the tongue and other soft tissues of the throat during sleep. Since FDA approval in April 2014, the company has reached its 1,000th implant and trained more than 100 medical centers that are actively implanting the device; patients use the device an average of seven or more hours per night. Inspire therapy is available at leading centers across the United States and Europe and is on the Federal Supply Schedule. Reimbursement progress includes case-by-case coverage from over 140 private insurers and Medicare reimbursement based on medical necessity in many U.S. geographies. The company plans to use recent funding to drive market adoption and reimbursement, broaden marketing, increase sales and operations, and continue building clinical evidence including an imminent German Post-Market Study and forthcoming 5-year STAR pivotal trial results. Inspire Medical Systems is a Minneapolis-based developer of a fully implanted and FDA-approved neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA). The company launched the Inspire® Upper Airway Stimulation (UAS) therapy in the United States, a fully implanted device for a subset of patients with moderate to severe OSA who are unable to use CPAP devices. The system uses neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. Tim Herbert is president and CEO. The company completed a $40M Series E financing and intends to use the funds to hire new people and make sales efforts. The financing supports the company’s commercial expansion of its UAS therapy. Inspire Medical Systems develops implantable Upper Airway Stimulation (UAS) neurostimulation therapy to treat obstructive sleep apnea (OSA). Its device delivers mild stimulation to the hypoglossal nerve synchronized with each breathing cycle to prevent tongue collapse and airway obstruction; patients activate therapy with a handheld programmer. The company completed enrollment and device implants in the STAR pivotal trial, which will form the basis for a Pre‑Market Approval (PMA) submission to the FDA targeted for early 2013. Inspire received CE Mark in 2010 and has completed commercial implants in Germany, Italy and The Netherlands; feasibility study results were published in Laryngoscope in May 2012. The company was formed in 2007 as a spin‑out from Medtronic and is based in Minneapolis, Minnesota. It completed a $14.5 million Series C to support clinical trial follow‑up, U.S. regulatory submissions, and expansion of commercial activities in Europe.

Total raised

$92M

Funding rounds

3

Latest round

Series F

Latest activity

Nov 2016